手术：结直肠癌肝转移治疗后的KRAS突变与肝复发 - Suppr

Surgery: KRAS mutations and hepatic recurrence after treatment of colorectal liver metastases.

作者信息

Brudvik Kristoffer Watten, Vauthey Jean-Nicolas

机构信息

Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, Texas 77030, USA.

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):638-639. doi: 10.1038/nrgastro.2017.129. Epub 2017 Sep 20.

DOI:10.1038/nrgastro.2017.129

PMID:28930294

Abstract

摘要

相似文献

Surgery: KRAS mutations and hepatic recurrence after treatment of colorectal liver metastases.

Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):638-639. doi: 10.1038/nrgastro.2017.129. Epub 2017 Sep 20.

Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Cancer. 2016 Sep 1;122(17):2698-707. doi: 10.1002/cncr.30085. Epub 2016 May 31.

Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.

Cancer. 2017 Feb 15;123(4):568-575. doi: 10.1002/cncr.30351. Epub 2016 Oct 13.

Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.

Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8.

Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.

Ann Surg Oncol. 2015 Dec;22(13):4158-65. doi: 10.1245/s10434-015-4587-z. Epub 2015 Jun 16.

Relationships among mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.

World J Gastroenterol. 2019 Feb 21;25(7):808-823. doi: 10.3748/wjg.v25.i7.808.

The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.

J Surg Oncol. 2018 Mar;117(4):745-755. doi: 10.1002/jso.24910. Epub 2017 Nov 30.

KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.

Ann Surg Oncol. 2016 Jun;23(6):1890-6. doi: 10.1245/s10434-016-5087-5. Epub 2016 Jan 19.

From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.

Surg Oncol. 2016 Sep;25(3):332-8. doi: 10.1016/j.suronc.2016.07.002. Epub 2016 Jul 14.

High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.

Oncol Rep. 2017 Feb;37(2):785-792. doi: 10.3892/or.2016.5323. Epub 2016 Dec 15.

引用本文的文献

RAS Mutations Predict Recurrence-Free Survival and Recurrence Patterns in Colon Cancer: A Unicenter Study in Morocco.

Cancer Control. 2024 Jan-Dec;31:10732748241229290. doi: 10.1177/10732748241229290.

Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases.

Cancers (Basel). 2022 Feb 5;14(3):816. doi: 10.3390/cancers14030816.

Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis: a narrative review.

Hepatobiliary Surg Nutr. 2020 Dec;9(6):705-716. doi: 10.21037/hbsn.2019.10.05.

Colorectal liver metastases: Current management and future perspectives.

World J Clin Oncol. 2020 Oct 24;11(10):761-808. doi: 10.5306/wjco.v11.i10.761.

Laparoscopic liver resection for non-colorectal non-neuroendocrine metastases: perioperative and oncologic outcomes.

World J Surg Oncol. 2019 Sep 4;17(1):156. doi: 10.1186/s12957-019-1700-y.

The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.

J Gastrointest Surg. 2019 Oct;23(10):1957-1963. doi: 10.1007/s11605-018-3978-4. Epub 2018 Oct 1.

Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?

J Gastrointest Surg. 2018 Jul;22(7):1286-1296. doi: 10.1007/s11605-018-3766-1. Epub 2018 Apr 11.

本文引用的文献

Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.

Ann Surg. 2017 Oct;266(4):641-649. doi: 10.1097/SLA.0000000000002367.

Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.

Br J Surg. 2017 May;104(6):760-768. doi: 10.1002/bjs.10490. Epub 2017 Feb 27.

RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.

Ann Surg Oncol. 2016 Aug;23(8):2635-43. doi: 10.1245/s10434-016-5187-2. Epub 2016 Mar 25.

Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma.

J Hepatol. 2016 Mar;64(3):594-600. doi: 10.1016/j.jhep.2015.10.015. Epub 2015 Oct 24.

Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

Br J Surg. 2015 Sep;102(10):1175-83. doi: 10.1002/bjs.9870. Epub 2015 Jul 21.

RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Ann Surg. 2013 Oct;258(4):619-26; discussion 626-7. doi: 10.1097/SLA.0b013e3182a5025a.

Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases.

J Gastrointest Surg. 2006 Jan;10(1):86-94. doi: 10.1016/j.gassur.2005.07.022.

Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

Ann Surg. 2005 May;241(5):715-22, discussion 722-4. doi: 10.1097/01.sla.0000160703.75808.7d.

Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.

Cancer Res. 2005 Feb 15;65(4):1244-50. doi: 10.1158/0008-5472.CAN-04-1911.

Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7. doi: 10.1097/01.sla.0000128305.90650.71.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Surgery: KRAS mutations and hepatic recurrence after treatment of colorectal liver metastases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献